Interim Results of a Risk-Adaptive Phase II Study: Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (KRD-Dara) in Newly Diagnosed Multiple Myeloma (NDMM) at the Levine Cancer Institute (LCI)

Saved in:
Bibliographic Details
Published in:Blood 2022-11, Vol.140 (Supplement 1), p.4440-4441
Main Authors: Bhutani, Manisha, Robinson, Myra, Paul, Barry, Atrash, Shebli, Varga, Cindy, Begic, Xhevahire, Foureau, David M, Pineda-Roman, Mauricio, Koya, Brinda, Norek, Sarah, Sutton, Sara A, Anderson, Michelle B, Acampora, Donna, Symanowski, James T, Voorhees, Peter M., Usmani, Saad
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:
ISSN:0006-4971
1528-0020
DOI:10.1182/blood-2022-160204